The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies

• Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit
• Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design
• Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates

Speakers:

Elaine Hurt

Executive Director & Head, Tumour Targeted Delivery Bioscience, Oncology R&D

AstraZeneca